CLINICAL TRIALS PROFILE FOR FLORBETAPIR F-18
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Florbetapir F-18
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00702143 ↗ | A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) | Completed | Avid Radiopharmaceuticals | Phase 2 | 2008-06-01 | Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI). |
| NCT00857415 ↗ | Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain | Completed | Avid Radiopharmaceuticals | Phase 3 | 2008-12-01 | The study is designed to test the relationship between measurements of brain amyloid using florbetapir F 18 PET imaging and true levels of amyloid by dissection of the brain at autopsy. Amyloid in the brain is a key feature of Alzheimer's Disease (AD). |
| NCT00857506 ↗ | Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45) | Completed | Avid Radiopharmaceuticals | Phase 2 | 2009-01-01 | The primary objective of this protocol is to determine if brain amyloid imaged with florbetapir F 18 (18F-AV-45) PET scans is predictive of progressive cognitive impairment during the subsequent 36 months for groups of: normal controls, mild cognitive impairment and Alzheimer's disease. Hypothesis 1: The probability a subject will experience progressive cognitive impairment within 36 months of imaging will be greater in subjects whose 18F-AV-45 PET scan was rated amyloid positive compared to subjects whose PET scan was rated amyloid negative. The secondary objective is to determine the stability, over 36 months of a clinical diagnosis, of AD in patients with an amyloid positive 18F-AV-45 PET. Hypothesis 2: The diagnosis of AD will remain unchanged in patients whose PET scan were rated as amyloid positive. |
| NCT00857532 ↗ | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 2 | 2009-01-01 | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. |
| NCT00857532 ↗ | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | Completed | National Institutes of Health (NIH) | Phase 2 | 2009-01-01 | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. |
| NCT00857532 ↗ | Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease Patients | Completed | Avid Radiopharmaceuticals | Phase 2 | 2009-01-01 | The primary aim of this study is to compare regional amyloid burden in Parkinson's disease (PD) to normal control subjects. We hypothesize that there will be significant differences in overall amyloid burden in PD patients compared to age-matched normal controls. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Florbetapir F-18
Condition Name
Clinical Trial Locations for Florbetapir F-18
Trials by Country
Clinical Trial Progress for Florbetapir F-18
Clinical Trial Phase
Clinical Trial Sponsors for Florbetapir F-18
Sponsor Name
